ACCG-2671 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-03 (month) in 4mo
ESTIMATED |
READOUT
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Eff
Phase 1/2 · Obesity |
Aconcagua Bio, Inc. a wholly owned | ACCG-2671 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-02
Sponsor-projected date — can change
|